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Abstract
The Gypsies are a trans-national founder population of Asian descent, whose genetic heritage is still incompletely characterized. Here,
we describe the Wrst founder mutation leading to a lysosomal storage disorder in this population: R59H in GLB1, which causes infantile
GM1-gangliosidosis. The R59H carrier rate is »2% in the general Gypsy population and »10% in the Rudari sub-isolate. Haplotype
analysis suggests that the Gypsy diaspora may have contributed to the spread of this mutation to South America.
© 2006 Elsevier Inc. All rights reserved.
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The Roma/Gypsies are a young founder population of
Asian origins nowadays scattered across the world, whose
demographic history has contributed to strong drift eVects
and a high frequency of autosomal recessive disease-caus-
ing mutations [1]. Previous studies of inborn errors of
metabolism have focused on disorders covered by mass
newborn screening: phenylketonuria and medium chain
acyl-coenzyme A dehydrogenase deWciency, caused by
mutations “imported” from the surrounding populations
(reviewed in [2]), and galactokinase deWciency, where a
unique ancestral mutation accounts for Gypsy patients
across Europe [3]. Here, we report on the Wrst lysosomal
storage disorder found to occur at high frequency in this
population: infantile GM1-gangliosidosis (MIM # 230500),
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doi:10.1016/j.ymgme.2005.12.009where deWciency of acid -galactosidase (EC 3.2.1.23) leads
to accumulation of glycosaminoglycans and glycopeptides
in visceral organs, and of GM1-ganglioside in neural tissue
[4]. The infantile form is characterized by early onset, mas-
sive nervous system involvement, skeletal dysplasias, viscer-
omegaly, and rapid progression to death [5]. The global
incidence of infantile GM1-gangliosidosis is estimated at
1:100,000–300,000, with higher frequencies observed in the
Maltese Islands (1:3700) and southern Brazil (1:17,000)
[6,7]. This study was prompted by the observed over-repre-
sentation of Gypsy patients among cases of infantile GM1-
gangliosidosis diagnosed in Bulgaria over 25 years
(expected 2–3, observed 11 out of 25 cases), suggesting an
ancestral mutation and founder eVect.
Subjects and methods
The study included 12 aVected Gypsy families, 11 residing in Bulgaria
and one in Italy [8,9], none of which were aware of any relatedness. The
total number of aVected children was 15, including two prenatally
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lies. The study complies with the ethical guidelines of the institutions
involved.
The age at the time of referral ranged between 3 and 9 months.
AVected children presented with facial dysmorphism (100%), retarded psy-
chomotor development (100%), hepatosplenomegaly (100%), muscle
hypotonia (82%), and ocular abnormalities, including a cherry red spot
(55%). Bone abnormalities and limited joint mobility were documented in
Wve cases. Two patients had skin abnormalities. Two others, referred by a
paediatric cardiology clinic, had hypertrophic cardiomyopathy. The age at
death, known in six cases, was <2 years. Total urinary glycosaminoglycan
excretion [10] was normal. Thin-layer chromatography of urinary
oligosaccharides [11] identiWed a characteristic pattern, suggesting GM1-
gangliosidosis. -Galactosidase enzyme activity, determined using 4-meth-
ylumbelliferyl -D-galactopyranoside [12], was 0.9–7.8 nmol/h/mg protein
in white blood cells (normal range 72–390), 6–17.4 nmol/h/mg protein in
Wbroblasts (normal range 375–1100), and 1.3 and 5.7 nmol/h/mg protein in
cultured amniotic Xuid cells (normal range 350–1150 nmol/h/mg protein).
-Glucuronidase, used as a control enzyme, was normal.
Sequencing analysis of the GLB1 gene on chromosome 3p21.33 [13,14]
was performed using primers as described [15] and ABI Big Dye 3.1. chem-
istry. The products were run on an ABI 377 DNA Analyzer, with
Sequence Navigator used for data analysis. Intragenic GLB1 polymor-
phisms L10P (rs7637099), L12L (rs7614776), R521C (rs4302331), and
S532G (a putative mutation/polymorphism not listed in SNP databases)
[15] were analysed by sequencing exons 1 and 15. Population screening for
the R59H mutation was done in a panel of 413 anonymous controls, repre-
senting diVerent Gypsy sub-isolates in Bulgaria [16,17]. We used a PCR-
based RFLP assay (NlaIII site created by the mutation) where exon 2 was
ampliWed with a HEX-labeled forward primer 5-catccttgctctgtagaatg-3
and reverse primer 5-acagttgtatcttctctccag-3, and restriction fragments
were length-separated on an ABI 377 DNA Analyzer.
Results and discussion
We identiWed a G > A transition in exon 2 of GLB1,
c.176G > A, resulting in the substitution of histidine for a
highly conserved arginine residue at position 59 (R59H).
Bulgarian Gypsy disease chromosomes shared a conserved
intragenic polymorphic haplotype (Table 1), supporting the
assumption of a common ancestral mutation.
R59H is a known mutation reported previously in GM1-
gangliosidosis patients in other parts of the world: two
homozygous siblings from Italy (patients 2.1 and 2.2 in
[8,9]) and eight aVected subjects from Brazil (patients 1–8 in
[15]). To test the possibility of a common origin, we re-
examined the family history of the aVected siblings diag-
nosed in Italy and established that the parents were Gypsy
migrants from the Balkans. Analysis of GLB1 polymor-
phisms showed that these patients were homozygous for
the same haplotype as observed in Gypsy disease chromo-
somes from Bulgaria (Table 1). In Brazil, R59H accounts
for over 20% of GM1-gangliosidosis alleles (in 9 out of the
40 disease chromosomes reported in [15]), with diVerent
Table 1
Comparison of intragenic polymorphic haplotypes of R59H alleles
L10P L12L (c34C > T) R59H R521C S532G
Gypsy-Bulgaria + + + ¡ ¡
Gypsy-Italy + + + ¡ ¡
Brazilian 1 ¡ ¡ + ¡ +
Brazilian 2 + + + ¡ ¡polymorphic haplotypes suggesting a recurrent mutation.
Our comparison with the haplotypes inferred from the pub-
lished Brazilian data showed that the ancestral Gypsy hap-
lotype is identical to the less common haplotype of
Brazilian R59H alleles (referred to as “Brazilian 2”  in the
Table below; present in patients 3, 6, and 7 in Table 2 of
[15]), supporting the possibility of a founder mutation
spreading to South America with the Gypsy diaspora. Bal-
kan Roma, a substantial proportion of the Gypsy commu-
nity of Brazil, reached South America in the late 19th–early
20th century, as part of the large migration wave out of
Romania after the abolition of Gypsy slavery [18].
The screening of a panel of 413 anonymous unrelated
control subjects identiWed eight heterozygotes, i.e., a carrier
rate of 1.94% in the general Gypsy population and a pre-
dicted incidence of aVected homozygotes 1 in »10,000 new-
borns. The distribution was non-random: all carriers were
detected among the 81 samples from a speciWc Gypsy
group, the Rudari—an endogamous sub-isolate well repre-
sented in the Gypsy communities of both Bulgaria and Bra-
zil [1,18], where the estimated carrier rate is 10%.
The pathogenic eVects of the R59H mutation have been
documented in in vitro studies [9]. All our cases displayed
the classical infantile GM1-gangliosidosis phenotype. The
association of R59H with cardiomyopathy, reported in the
Italian patients [8,9], was also present in two of the aVected
children from Bulgaria, and may have gone undetected in
the others. The data presented here should stimulate future
phenotype studies in the genetically homogeneous group of
R59H homozygotes.
Our results place GM1-gangliosidosis among the com-
mon Mendelian disorders in the Gypsy population. R59H
testing should be the Wrst choice procedure in Gypsy chil-
dren with the clinical manifestations of a lysosomal storage
disorder, and may be particularly useful in couples with an
infant deceased from an undiagnosed condition compatible
with GM1-gangliosidosis. Our Wndings should facilitate the
diagnostic process and allow prenatal analysis, an option to
which aVected families have been highly receptive.
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